Defining eligible patients for allele-selective chemotherapies targeting NAT2 in colorectal cancer
Abstract Therapies targeting somatic bystander genetic events represent a new avenue for cancer treatment. We recently identified a subset of colorectal cancer (CRC) patients who are heterozygous for a wild-type and a low activity allele (NAT2*6) but lack the wild-type allele in their tumors due to...
Guardado en:
Autores principales: | Veronica Rendo, Snehangshu Kundu, Natallia Rameika, Viktor Ljungström, Richard Svensson, Kimmo Palin, Lauri Aaltonen, Ivaylo Stoimenov, Tobias Sjöblom |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/0075eeada5c6431e9aaae378bc12e7b8 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Exploiting loss of heterozygosity for allele-selective colorectal cancer chemotherapy
por: Veronica Rendo, et al.
Publicado: (2020) -
Confessions of Nat Turner
por: Nat Turner
Publicado: (2009) -
The differential effect of NAT2 variant alleles permits refinement in phenotype inference and identifies a very slow acetylation genotype.
por: Jhon D Ruiz, et al.
Publicado: (2012) -
Allelic and genotypic frequencies of NAT2, CYP2E1, and AADAC genes in a cohort of Peruvian tuberculosis patients
por: Kelly S. Levano, et al.
Publicado: (2021) -
Polimorfismo Nat2 y patología humana
por: García Menaya, Jesús Miguel
Publicado: (2001)